Novo Nordisk's Ability to Fight Back in Obesity Remains Key -- Market Talk

Dow Jones12-10

1402 GMT - Novo Nordisk shares trade at a low multiple, and the company's ability to fight back and regain its foothold in the obesity market remains key to driving investor confidence, HSBC writes. Most important in the fight back will be the launch of oral semaglutide in 2026. HSBC also says the market might need further evidence that the company is not deprioritizing the launch of obesity and diabetes treatment Cagrisema, otherwise Novo Nordisk faces a large loss of drug-patent exclusivity in 2032. "We think that the inflection point in the shares is unlikely to be before the full year guidance is issued by the company." The bank raises its target price on the stock to 350 Danish kroner from 300 kroner and keeps its hold rating. Shares rise 1.4% to 303.40 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

December 10, 2025 09:02 ET (14:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590388615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590388615","market":"sh","top_or_hot":-1,"title":"Novo Nordisk's Ability to Fight Back in Obesity Remains Key -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1402 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> shares trade at a low multiple, and the company's ability to fight back and regain its foothold in the obesity market remains key to driving investor confidence, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> writes. Most important in the fight back will be the launch of oral semaglutide in 2026. HSBC also says the market might need further evidence that the company is not deprioritizing the launch of obesity and diabetes treatment Cagrisema, otherwise Novo Nordisk faces a large loss of drug-patent exclusivity in 2032. \"We think that the inflection point in the shares is unlikely to be before the full year guidance is issued by the company.\" The bank raises its target price on the stock to 350 Danish kroner from 300 kroner and keeps its hold rating. Shares rise 1.4% to 303.40 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2025 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Ability to Fight Back in Obesity Remains Key -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Ability to Fight Back in Obesity Remains Key -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-10 22:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1402 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> shares trade at a low multiple, and the company's ability to fight back and regain its foothold in the obesity market remains key to driving investor confidence, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> writes. Most important in the fight back will be the launch of oral semaglutide in 2026. HSBC also says the market might need further evidence that the company is not deprioritizing the launch of obesity and diabetes treatment Cagrisema, otherwise Novo Nordisk faces a large loss of drug-patent exclusivity in 2032. \"We think that the inflection point in the shares is unlikely to be before the full year guidance is issued by the company.\" The bank raises its target price on the stock to 350 Danish kroner from 300 kroner and keeps its hold rating. Shares rise 1.4% to 303.40 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2025 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128525689.USD","symbol_name":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590388615","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590388615","pubTimestamp":1765375320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1402 GMT - Novo Nordisk shares trade at a low multiple, and the company's ability to fight back and regain its foothold in the obesity market remains key to driving investor confidence, HSBC writes. Most important in the fight back will be the launch of oral semaglutide in 2026. HSBC also says the market might need further evidence that the company is not deprioritizing the launch of obesity and diabetes treatment Cagrisema, otherwise Novo Nordisk faces a large loss of drug-patent exclusivity in 2032. \"We think that the inflection point in the shares is unlikely to be before the full year guidance is issued by the company.\" The bank raises its target price on the stock to 350 Danish kroner from 300 kroner and keeps its hold rating. Shares rise 1.4% to 303.40 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4588":"碎股","HSBC":"汇丰","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","BK4207":"综合性银行","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK4521":"英国银行股"},"translate_title":"诺和诺德对抗肥胖的能力仍然是关键——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96,"HSBC":0.7},"content_text":"1402 GMT - Novo Nordisk shares trade at a low multiple, and the company's ability to fight back and regain its foothold in the obesity market remains key to driving investor confidence, HSBC writes. Most important in the fight back will be the launch of oral semaglutide in 2026. HSBC also says the market might need further evidence that the company is not deprioritizing the launch of obesity and diabetes treatment Cagrisema, otherwise Novo Nordisk faces a large loss of drug-patent exclusivity in 2032. \"We think that the inflection point in the shares is unlikely to be before the full year guidance is issued by the company.\" The bank raises its target price on the stock to 350 Danish kroner from 300 kroner and keeps its hold rating. Shares rise 1.4% to 303.40 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 09:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590388615","isCrawlerRequest":true}